GODKJENT PROSPEKT

NOT  FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN  WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, OR SWITZERLAND, OR  ANY OTHER  JURISDICTION IN  WHICH THE  PUBLICATION, DISTRIBUTION  OR RELEASE WOULD  BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, 5. april 2013

Det vises til børsmelding offentliggjort av DiaGenic ASA (“Selskapet”) 2. april 2013 vedrørende avholdt ekstraordinær generalforsamling hvor den rettede emisjonen ("Rettede Emisjonen") på 50 000 000 nye aksjer (de “Nye Aksjene”) og den etterfølgende reparasjonsemisjonen (det "Etterfølgende Tilbudet") på opptil 11 666 666 nye aksjer ("Tilbudsaksjene") ble godkjent.

Finanstilsynet har i dag, den 5. april 2013, godkjent prospektet for (i) notering av de Nye Aksjene på Oslo Børs, (ii) det Etterfølgende Tilbudet og notering av Tilbudsaksjene, med tegningsretter (”Tegningsrettene”) som utstedes til Selskapets aksjeeiere per 7. mars 2013, som registrert i VPS per 12. mars 2013, som ikke ble tildelt Nye Aksjer i den Rettede Emisjonen, og (iii) notering av Tegningsrettene på Oslo Børs (“Prospektet”).

Kapitalforhøyelsen i forbindelse med det rettede Tilbudet forventes registrert i Foretaksregisteret 8. april 2013. De Nye Aksjene er forventet notert på Oslo Børs samme dag.

Tegningsperioden i det Etterfølgende Tilbudet samt noteringen av Tegningsrettene på Oslo Børs vil starte den 9. april 2013 og avsluttes den 23. april 2013 kl. 16:30 (norsk tid). Tegningskurs per Tilbudsaksje er NOK 0,60, tilsvarende tegningskursen i den Rettede Emisjonen.

Prospektet og tegningsblanketten for det Etterfølgende Tilbudet er tilgjengelig på www.diagenic.com, www.dnb.no/emisjoner og i trykket versjon på kontorene til DiaGenic ASA og DNB Markets som henholdsvis er Grenseveien 92, 0663 Oslo og Dronning Eufemias gate 30, 0021 Oslo, i tilbudsperioden.

For ytterlige informasjon knyttet til den Rettede Emisjonen og det Etterfølgende Tilbudet henvises det til Prospektet.

DNB Markets, en del av DNB Bank ASA, er tilrettelegger for den Rettede Emisjonen og det Etterfølgende Tilbudet.

For ytterligere informasjon kontakt:

Henrik Lund, Styreleder, DiaGenic ASA, Telefon +47 90 97 12 19

Paul de Potocki, Adm. dir., DiaGenic ASA, Telefon +47 23 24 89 67

Important Notice

The contents of this announcement have been prepared by, and are the sole responsibility of, the Company. The Company's manager is acting exclusively for the Company and no one else, and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients, or for advice in relation to the Private Placement, the Subsequent Offering, the contents of this announcement or any of the matters referred to herein. The Private Placement, the Subsequent Offering and the distribution of this announcement and other information in connection with the Private Placement and the Subsequent Offering may be restricted by law in certain jurisdictions. The Company assumes no responsibility in the event there is a violation by any person of such restrictions. Persons into whose possession this announcement or such other information should come are required to inform themselves about, and to observe, any such restrictions. This announcement may not be used for, or in connection with, and does not constitute, any offer of securities for sale in the United States or in any other jurisdiction.

The Private Placement and the Subsequent Offering will not be made in any jurisdiction or in any circumstances in which such offer or solicitation would be unlawful. This announcement is not for distribution, directly or indirectly in or into any jurisdiction in which it is unlawful to make any such offer or solicitation to such person or where prior registration or approval is required for that purpose. No steps have been taken or will be taken relating to the Private Placement or the Subsequent Offering in any jurisdiction outside of Norway in which such steps would be required. Neither the publication and/or delivery of this announcement shall under any circumstances imply that there has been no change in the affairs of the Company or that the information contained herein is correct as of any date subsequent to the earlier of the date hereof and any earlier specified date with respect to such information.

This announcement is not for publication or distribution, directly or indirectly, in the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form part of any offer or solicitation to purchase or subscribe for securities in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration. The shares of the Company, including the shares to be issued in the Private Placement and the Subsequent Offering, have not been and will not be registered under the United States Securities Act of 1933, as amended (the "US Securities Act") or with any securities regulatory authority of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to, or for the account of, U.S. persons (as such term is defined in Regulation S under the US Securities Act), except pursuant to an effective registration statement under, or an exemption from the registration requirements of, the US Securities Act. All offers and sales outside the United States will be made in reliance on Regulation S under the US Securities Act. There will be no public offer of securities in the United States.

This announcement does not constitute an offering circular or prospectus in connection with an offering of securities of the Company. Investors must neither accept any offer for, nor acquire, any securities to which this document refers, unless they do so on the basis of the information contained in relevant offering documentation to be distributed and made available by the Company only to qualified persons in certain jurisdictions where an offer may be made (if an offer is made). This announcement does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for, any securities and cannot be relied on for any investment contract or decision.

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Om DiaGenic ASA

DiaGenic skaper merverdi for pasienter, partnere og investorer gjennom utvikling av innovative og pasientvennlige in vitro diagnostiske (IVD) produkter for tidlig diagnose av sykdommer. Selskapets proprietære konsept innebærer at en sykdom fremkaller systemiske reaksjoner i blodet unik for sykdommen, og som kan måles ved hjelp av en blodprøve. DiaGenic er verdensledende i å identifisere genekspresjonssignaturer i blod og er fokusert på utvikling av biomarkør baserte IVD produkter innen Alzheimers sykdom. Selskapet beskytter sin teknologi gjennom en omfattende patentportefølje. DiaGenic er et norsk selskap notert på Oslo Børs. For mer informasjon vennligst besøk: www.diagenic.com

Om oss

DiaGenic ASA is an innovative Norwegian life sciences company founded in 1998 and listed on the Oslo Stock Exchange. DiaGenic develops patient-friendly tests for the early diagnosis of devastating diseases where early intervention is crucial for successful treatment. DiaGenic’s patented method is based on identifying disease-specific gene signatures from easily available sample material such as blood. DiaGenic's strategy is to work with research and technology partners to develop a pipeline of assays for commercialisation by major diagnostics companies. Currently DiaGenic’s first two tests for the early detection of breast cancer and Alzheimer’s disease are on track to enter extensive clinical trials during 2007. The company has been awarded substantial development grants as part of the Norwegian Research Council’s FUGE programme.

Abonner